TY - JOUR
T1 - Connecting the brain and new drug targets for schizophrenia
AU - Whalley, H.C.
AU - Steele, J.D.
AU - Mukherjee, P.
AU - Romaniuk, L.
AU - McIntosh, A.M.
AU - Hall, J.
AU - Lawrie, S.M.
N1 - MEDLINE® is the source for the MeSH terms of this document.
PY - 2009/8/1
Y1 - 2009/8/1
N2 - One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/ or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.
AB - One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/ or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.
UR - http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-69249111873&md5=3727cc44baf19e304f9024fea7e2808b
U2 - 10.2174/138161209788957500
DO - 10.2174/138161209788957500
M3 - Literature review
C2 - 19689332
AN - SCOPUS:69249111873
SN - 1381-6128
VL - 15
SP - 2615
EP - 2631
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 22
ER -